Trastuzumab Combined With Pyrrolidine and Chemotherapy for Locally HER2 Positive Breast Cancer

Exclusion Criteria

• •1. Have received any previous anti-tumor treatment for primary invasive breast cancer;
• •2. Previous (\<10 years) or other malignant tumors, except for curable cancer species: a. basal cell carcinoma of skin and squamous cell carcinoma b. Carcinoma in situ of cervix
• •3. For patients with other malignancies, they can also be included in the study if the time from diagnosis to enrollment exceeds 10 years; Prior surgical treatment is permitted except for radiotherapy or systemic therapy (chemotherapy or endocrine therapy);
• •4. Metastatic breast cancer (M1), bilateral or ipsilateral multifocal breast cancer;
• •5. Uncontrolled hypertension, systolic blood pressure \> 150 MMHG and/or diastolic blood pressure \> 100 MMHG), or clinical symptomatic cardiovascular disease, myocardial ischemia and myocardial infarction, severe/unstable angina, poor control of cardiac arrhythmias (including women according to Bazett formula correction QTc interphase \< 470 ms), symptoms of congestive heart failure, cerebrovascular accident (including transient ischemic attack or symptomatic cerebral embolism), NYHA Ⅱ magnitude cardiac insufficiency;
• •6. Receive other anti-tumor treatments within 4 weeks before enrollment;
• •7. Inability to swallow, intestinal obstruction or other factors affecting the use and absorption of medication;
• •8. Persons with allergic constitution or known history of allergy to the drug components of the program;
• •9. The patient has a severe concomitant disease or other conditions that the researcher considers inappropriate for the patient to participate in the studyIn any case;
• •10. Non-surgically sterilized female patients of childbearing age must have negative serum or urine HCG tests within 14 days prior to study inclusion; And must be non-lactation
• •11. Other circumstances deemed inappropriate for inclusion by the researcher.